Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com.
The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer .
Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK — is intended for people with primary advanced or recurrent forms of the cancer, according to the FDA’s Aug. 1 announcement. It is an immunotherapy-based drug, which means it leverages the body’s immune system to attack cancer cells.
SOME TAMPON PRODUCTS FOUND TO CONTAIN TOXIC METALS IN FIRST-TIME STUDY: 'HARMFUL INGREDIENTS' In clinical trials , Jemperli showed an improved progression-free survival and overall survival for all patients, according to Dr. Brian Slomovitz, director of gynecologic oncology and co-chair of the Cancer Research Committee at Mount Sinai Medical Center in Florida. "This class of drugs has been used in the second-line setting," Slomovitz said — meaning they were only used if a first-line (primary) treatment was not effective or had intolerable side effects.
The FDA has approved a new drug for certain adult patients with endometrial cancer. (iStock) "Moving them to first-line [status] here will yield better outcomes." This is the third FDA approval this year for immunotherapy in endometrial cancer , the doctor noted.
THE 9 MOST COMMON QUESTIONS WOMEN OVER 40 ASK THEIR DOCTORS, ACCORDING TO A MENOPAUSE EXPERT "This is great news for our patients," Slomovitz told Fox News Di.